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Abstract
Typhoid vaccination is recommended in the United States before travel to countries where typhoid 
fever is endemic, though little information is available on its effectiveness in travelers.
We estimated typhoid vaccination effectiveness (VE) by comparing vaccination status in cases of 
typhoid fever and paratyphoid fever (Salmonella Paratyphi A infection, against which typhoid 
vaccine offers no protection) reported in the United States. We included travelers to Southern Asia 
and excluded persons <2 years old and cases in which vaccination status was not reported.
From 2008 through 2011, 744 eligible cases (602 typhoid, 142 paratyphoid A) were reported to 
CDC. Typhoid vaccination was reported for 5% (29/602) of typhoid patients and for 20% (29/142) 
of paratyphoid A patients. Estimated VE was 80% (95% confidence interval, 66–89%). Because 
of missing data, we could not estimate VE for specific vaccines.
We demonstrated moderate effectiveness of typhoid vaccination in US travelers, supporting 
vaccination recommendations.
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1. Introduction
Typhoid vaccination is recommended in the United States before travel to countries where 
typhoid fever is endemic [1–3]. Two vaccines are available – live, oral Ty21a (Vivotif®, 
Crucell/Berna) and typhoid Vi polysaccharide (Typhim Vi®, Sanofi Pasteur) – but little 
information exists on their effectiveness in travelers.
*Corresponding author. Tel.: +1 404 718 1157; fax: +1 404 639 2205. bmahon@cdc.gov.
aenewton@cdc.gov (A.E. Newton), emintz@cdc.gov (E.D. Mintz).
Conflict of interest statement
All author declare no conflict of interests.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2015 October 14.
Published in final edited form as:
Vaccine. 2014 June 17; 32(29): 3577–3579. doi:10.1016/j.vaccine.2014.04.055.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Typhoid fever is caused by infection with Salmonella enterica serotype Typhi. It is 
clinically indistinguishable from paratyphoid fever, which is most often caused by infection 
with S. enterica serotype Paratyphi A but can also be caused by Paratyphi B and C. Illness is 
characterized by fever, abdominal pain, and malaise that can last for weeks and can cause 
severe outcomes such as intestinal perforation or death [4]. Both are transmitted primarily 
through contaminated food or water and are uncommon in the United States; most cases 
occur in persons who have recently traveled in countries where these diseases are endemic. 
Travel to Southern Asia, (primarily India, Pakistan, and Bangladesh) accounts for most 
typhoid and paratyphoid fever cases in the United States [5–7].
Although Ty21a may provide some protection against Paratyphi B infection, neither vaccine 
provides protection against paratyphoid fever caused by Paratyphi A [8,9]. Therefore, 
vaccination rates among returning travelers with typhoid fever can be compared with rates 
among those with paratyphoid fever caused by Paratyphi A to infer the degree of protection 
provided by vaccination. We used surveillance data to estimate the effectiveness of typhoid 
vaccination in US travelers.
2. Material and methods
State and local health officials report culture-confirmed typhoid and paratyphoid fever to the 
Centers for Disease Control and Prevention (CDC) through the National Typhoid and 
Paratyphoid Fever Surveillance (NTPFS) system [10]. This system, which initially included 
only typhoid fever, was expanded in 2007 to include paratyphoid fever. The standard case 
report includes information on patient demographics, travel history including destination 
countries and reason for travel, whether the patient received a typhoid vaccine in the 5 years 
before illness onset, and, if so, which vaccine.
We analyzed data on reported cases of typhoid fever (hereafter called typhoid) and of 
paratyphoid fever caused by Salmonella serotype Paratyphi A infection (hereafter called 
paratyphoid A) occurring from 2008 through 2011. For the vaccine effectiveness analysis, 
we included cases in travelers, defined as persons who spent time outside of the United 
States in the 30 days before illness began. Because Paratyphi A is primarily reported from 
Southern Asiai, we excluded travelers who did not travel to this region [11]. Children <2 
years old, who were too young for typhoid vaccination, and cases in which vaccination 
status was not reported were excluded.
We calculated descriptive statistics for typhoid and paratyphoid A. Using conditional 
logistic regression, we calculated the odds ratio (OR) with 95% confidence intervals (95% 
CI) for vaccination among travelers with typhoid, compared with those with paratyphoid A, 
and we estimated typhoid vaccination effectiveness (VE) as (1 − OR) × 100%. We assessed 
confounding by constructing models that included citizenship status and reason for travel, 
considering a change in the OR for vaccination of >10% as indicating confounding. We used 
SAS 9.3 (Cary, NC) for analyses.
iAs defined by the United Nations, includes Afghanistan, Bangladesh, Bhutan, India, Iran (Islamic Republic of), Maldives, Nepal, 
Pakistan, and Sri Lanka.
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3. Results
During 2008–2011, 1171 travelers ≥2 years old were reported with typhoid and 318 with 
paratyphoid A; 956 (82%) with typhoid and 306 (96%) with paratyphoid A reported travel 
to Southern Asia. Among these, vaccination status was available for 602 (63%) typhoid and 
142 (43%) paratyphoid A patients; these 744 cases were included in the analysis.
Demographic characteristics were similar among typhoid and paratyphoid A patients (Table 
1). Travel destinations were also similar. Visiting friends and relatives was the most 
common reason for travel and was more commonly reported for typhoid patients (71%) than 
paratyphoid A patients (66%, p = 0.04). United States citizenship was reported for a 
somewhat lower percentage of typhoid patients (221/331, 67%) than paratyphoid A patients 
(75/96, 78%, p = 0.03), though data were frequently missing (45% for typhoid, 33% for 
paratyphoid A).
Typhoid vaccination within 5 years before illness began was reported for 5% (29/602) of 
typhoid fever patients but for 20% (29/142) of paratyphoid A fever patients, yielding an 
estimated VE of 80% (95% CI, 66–89%.) Estimated VE did not change substantially in 
models adjusting for reason for travel or US citizenship status or both. The type of vaccine 
received was often not known; this information was missing for 69% (20/29) vaccinated 
typhoid patients and 28% (8/29) vaccinated paratyphoid A patients. Among vaccinated 
typhoid patients for whom the type of vaccine was reported, 3 (33%) had received the oral 
vaccine and 6 (67%) the parenteral vaccine. Among vaccinated paratyphoid A patients, 6 
(29%) had received the oral vaccine and 15 (71%) the parenteral vaccine.
4. Discussion
This study demonstrates moderate effectiveness of typhoid fever vaccination in US travelers 
and provides the first direct evidence of effectiveness in this group. This result reflects the 
effectiveness of adherence to the recommendation for typhoid vaccination for travelers in 
general, because we could not estimate the effectiveness of either US-licensed vaccine 
individually. Our estimate of 80% effectiveness is on the high end of the range of previous 
estimates of protection by both typhoid vaccines [12]. Typhoid vaccines have been less 
effective in situations with intense exposure to serotype Typhi than when the risk of 
exposure is lower [9]. Therefore, our relatively high effectiveness estimate suggests that the 
risk of serotype Typhi exposure might be lower, on average, for travelers than for persons 
living in endemic areas, perhaps because many travelers do not stay in endemic areas for 
months or years before returning to the United States or because they have less exposure to 
contaminated water and food than the local population.
We used paratyphoid A patients as controls for typhoid patients for a case-control analysis. 
This approach assumes that paratyphoid A and typhoid patients arise from the same source 
population and have the same risk of exposure to serotype Typhi during travel and the same 
likelihood of being diagnosed and reported after travel, and thus that the observed difference 
in vaccination rates between the two groups is due to protection induced by vaccination. A 
strength of our study is that the risk factors, clinical manifestations, and public health 
surveillance for paratyphoid A and typhoid in travelers are similar, so the likelihood of 
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exposure, diagnosis, and reporting to CDC were likely very similar as well. By restricting 
analysis to cases related to travel to Southern Asia, we further ensured similar opportunity 
for exposure. The fact that these groups were similar in terms of demographics, reasons for 
travel, and citizenship and that controlling for these factors did not substantially change the 
vaccination effectiveness estimate is also reassuring.
A second assumption is that typhoid vaccination provides no protection against paratyphoid 
A. Vi polysaccharide vaccine is thought to protect through stimulating a humoral response 
to Vi antigen, which is not present on Paratyphi A; thus, Vi vaccine does not protect against 
Paratyphi A infection. For Ty21a, the situation is less certain, because the mechanism of 
protection is not fully understood and because of laboratory evidence of some immunologic 
cross-reactivity to Paratyphi A after Ty21a vaccination [13–15]. However, efficacy studies 
in endemic areas have found no evidence of actual protection against infection [8,9]. If 
Ty21a did protect against Paratyphoid A, it would tend to lower our estimate of vaccine 
effectiveness.
Although NTPFS collects information on both diseases, only typhoid is nationally notifiable. 
Therefore, it is possible that reporting is more complete for typhoid than for paratyphoid A. 
However, unless reporting is associated with vaccination status, this difference would not 
bias the estimate of vaccination effectiveness. The lack of vaccination information for many 
reported cases of both diseases is more problematic. By decreasing the power of our 
analysis, this missing information likely lowered the precision of our vaccination 
effectiveness estimate. Again, though, it would not have biased the vaccination effectiveness 
estimate unless missing data led to spurious differences in the rates of vaccination in the two 
groups. Many reports in both groups that included vaccination information did not identify 
the specific vaccine administered; as a result, we could not estimate the effectiveness of each 
vaccine individually, only of typhoid vaccination in general.
Less than a quarter of paratyphoid A patients in our study had been vaccinated against 
typhoid. The fact that they acquired paratyphoid A shows that they were also at risk for 
typhoid, since both infections are transmitted by the same routes. This result is consistent 
with other studies that have shown a great deal of room for improvement in preventive 
measures for travelers, especially travelers visiting friends and relatives [16], the majority in 
our study.
In conclusion, our analysis of 4 years of US national surveillance data indicates that 
travelers to endemic areas can expect moderate protection from typhoid vaccination. It 
supports the recommendation for vaccination before travel to endemic areas and also 
emphasizes the importance of careful attention to food and water safety. Increased 
vaccination rates among travelers to endemic areas, especially travelers visiting friends and 
relatives, could have a substantial impact on travel-associated typhoid in the United States. 
Our results also highlight the need for an effective vaccine against paratyphoid A, which is 
an increasingly important cause of enteric fever in Asia [17] and could spread to other 
regions.
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Table 1
Characteristics of patients with typhoid (Salmonella serotype Typhi infection) or paratyphoid A (Salmonella 
serotype Paratyphi A infection) who were ≥2 years old, traveled to Southern Asia, and had known vaccination 
status reported to the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system, United States, 
2008–2011.
Typhoid N = 602 Paratyphoid A N = 142 p-Value
Median age, years (range) 23 (2–86) 25 (2–74) 0.07
Female n/N (%) 284/587 (48%) 60/141 (43%) 0.20
Travel destination in Southern Asia
 Single country 596 140
 India n (%) 416 (70%) 102 (73%) 0.53*
 Bangladesh n (%) 97 (16%) 25 (18%)
 Pakistan n (%) 75 (13%) 9 (6%)
 Nepal n (%) 8 (4%) 4 (3%)
 ≥2 countries† 6 2
Reason for travel
 Visit friends and relatives‡ (VFR) 425 (71%) 93 (66%) 0.04
 Business 28 (5%) 10 (7%)
 Tourism 24 (4%) 18 (13%)
 Immigration to US 35 (6%) 4 (3%)
 Other 38 (6%) 10 (7%)
 Unknown 52 (9%) 7 (5%)
United States citizen n/N (%) 221/331 (67%) 75/96 (78%) 0.03
Typhoid vaccination n/N (%) 29/602 (5%) 29/142 (20%) <0.0001
*
p-Value is for comparison of travel to India vs travel to a single country other than India.
†
Included combinations of India, Bangladesh, Pakistan, Nepal, and Sri Lanka.
‡
p-Value is for comparison of VFR travel vs any other reason for travel, including “other”, but excluding “unknown”.
Reported typhoid vaccination within 5 years before illness onset.
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